Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Novartis
Avenzo Therapeutics, Inc.
Shandong Suncadia Medicine Co., Ltd.
Incyclix Bio
Memorial Sloan Kettering Cancer Center
Terremoto Biosciences Inc.
Ellipses Pharma
Ensem Therapeutics
Hoffmann-La Roche
Criterium, Inc.
Pikavation Therapeutics, Inc.
Aminex Therapeutics, Inc.
Eli Lilly and Company
Novartis
Phoenix Molecular Designs